PMC:7253482 / 0-339
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2 | 19-30 | Species | denotes | coronavirus | Tax:11118 |
| 3 | 31-37 | Chemical | denotes | glycan | MESH:D011134 |
| 25 | 133-186 | Species | denotes | Middle East respiratory syndrome (MERS) coronaviruses | Tax:1335626 |
| 26 | 188-192 | Species | denotes | CoVs | Tax:11118 |
| 39 | 88-121 | Disease | denotes | Severe acute respiratory syndrome | MESH:D045169 |
| 40 | 123-127 | Disease | denotes | SARS | MESH:D045169 |
| 41 | 198-206 | Disease | denotes | zoonotic | MESH:D015047 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 88-121 | Disease | denotes | Severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T2 | 123-127 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 286-293 | http://purl.obolibrary.org/obo/CLO_0009985 | denotes | focuses |
LitCovid-sample-PD-IDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 207-216 | http://purl.obolibrary.org/obo/IDO_0000528 | denotes | pathogens |
LitCovid-sample-Enju
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 0-15 | NNS | denotes | Vulnerabilities |
| T1 | 16-18 | IN | denotes | in |
| T2 | 19-30 | NN | denotes | coronavirus |
| T3 | 31-37 | NN | denotes | glycan |
| T4 | 38-45 | NNS | denotes | shields |
| T5 | 46-53 | IN | denotes | despite |
| T6 | 54-63 | JJ | denotes | extensive |
| T7 | 64-77 | NN | denotes | glycosylation |
| T8 | 79-87 | NN | denotes | Abstract |
| T9 | 88-94 | JJ | denotes | Severe |
| T10 | 95-100 | JJ | denotes | acute |
| T11 | 101-112 | JJ | denotes | respiratory |
| T12 | 113-121 | NN | denotes | syndrome |
| T13 | 122-123 | -LRB- | denotes | ( |
| T14 | 123-127 | NN | denotes | SARS |
| T15 | 127-128 | -RRB- | denotes | ) |
| T16 | 129-132 | CC | denotes | and |
| T17 | 133-139 | NNP | denotes | Middle |
| T18 | 140-144 | NNP | denotes | East |
| T19 | 145-156 | JJ | denotes | respiratory |
| T20 | 157-165 | NN | denotes | syndrome |
| T21 | 166-167 | -LRB- | denotes | ( |
| T22 | 167-171 | NNS | denotes | MERS |
| T23 | 171-172 | -RRB- | denotes | ) |
| T24 | 173-186 | NNS | denotes | coronaviruses |
| T25 | 187-188 | -LRB- | denotes | ( |
| T26 | 188-192 | NNS | denotes | CoVs |
| T27 | 192-193 | -RRB- | denotes | ) |
| T28 | 194-197 | VBP | denotes | are |
| T29 | 198-206 | JJ | denotes | zoonotic |
| T30 | 207-216 | NNS | denotes | pathogens |
| T31 | 217-221 | IN | denotes | with |
| T32 | 222-226 | JJ | denotes | high |
| T33 | 227-235 | NN | denotes | fatality |
| T34 | 236-241 | NNS | denotes | rates |
| T35 | 242-245 | CC | denotes | and |
| T36 | 246-254 | JJ | denotes | pandemic |
| T37 | 255-264 | NN | denotes | potential |
| T38 | 266-273 | NN | denotes | Vaccine |
| T39 | 274-285 | NN | denotes | development |
| T40 | 286-293 | VBZ | denotes | focuses |
| T41 | 294-296 | IN | denotes | on |
| T42 | 297-300 | DT | denotes | the |
| T43 | 301-310 | JJ | denotes | principal |
| T44 | 311-317 | NN | denotes | target |
| T45 | 318-320 | IN | denotes | of |
| T46 | 321-324 | DT | denotes | the |
| T47 | 325-337 | VBG | denotes | neutralizing |
| R6 | T7 | T6 | arg1Of | glycosylation,extensive |
| R7 | T12 | T9 | arg1Of | syndrome,Severe |
| R8 | T12 | T10 | arg1Of | syndrome,acute |
| R9 | T12 | T11 | arg1Of | syndrome,respiratory |
| R0 | T0 | T1 | arg1Of | Vulnerabilities,in |
| R1 | T4 | T1 | arg2Of | shields,in |
| R2 | T4 | T2 | arg1Of | shields,coronavirus |
| R3 | T4 | T3 | arg1Of | shields,glycan |
| R4 | T0 | T5 | arg1Of | Vulnerabilities,despite |
| R5 | T7 | T5 | arg2Of | glycosylation,despite |
| R10 | T12 | T13 | arg1Of | syndrome,( |
| R11 | T14 | T13 | arg2Of | SARS,( |
| R12 | T15 | T13 | arg3Of | ),( |
| R13 | T12 | T16 | arg1Of | syndrome,and |
| R14 | T20 | T16 | arg2Of | syndrome,and |
| R15 | T18 | T17 | arg1Of | East,Middle |
| R16 | T20 | T18 | arg1Of | syndrome,East |
| R17 | T20 | T19 | arg1Of | syndrome,respiratory |
| R18 | T20 | T21 | arg1Of | syndrome,( |
| R19 | T22 | T21 | arg2Of | MERS,( |
| R20 | T23 | T21 | arg3Of | ),( |
| R21 | T28 | T24 | arg1Of | are,coronaviruses |
| R22 | T24 | T25 | arg1Of | coronaviruses,( |
| R23 | T26 | T25 | arg2Of | CoVs,( |
| R24 | T27 | T25 | arg3Of | ),( |
| R25 | T16 | T28 | arg1Of | and,are |
| R26 | T30 | T28 | arg2Of | pathogens,are |
| R27 | T30 | T29 | arg1Of | pathogens,zoonotic |
| R28 | T30 | T31 | arg1Of | pathogens,with |
| R29 | T35 | T31 | arg2Of | and,with |
| R30 | T34 | T32 | arg1Of | rates,high |
| R31 | T34 | T33 | arg1Of | rates,fatality |
| R32 | T34 | T35 | arg1Of | rates,and |
| R33 | T37 | T35 | arg2Of | potential,and |
| R34 | T37 | T36 | arg1Of | potential,pandemic |
| R35 | T39 | T38 | arg1Of | development,Vaccine |
| R36 | T39 | T40 | arg1Of | development,focuses |
| R37 | T40 | T41 | arg1Of | focuses,on |
| R38 | T44 | T41 | arg2Of | target,on |
| R39 | T44 | T42 | arg1Of | target,the |
| R40 | T44 | T43 | arg1Of | target,principal |
| R41 | T44 | T45 | arg1Of | target,of |
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T1 | 88-121 | Species | denotes | Severe acute respiratory syndrome | NCBItxid:694009 |
| T2 | 123-127 | Species | denotes | SARS | NCBItxid:694009 |
| T3 | 167-171 | Species | denotes | MERS | NCBItxid:1335626 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-77 | Sentence | denotes | Vulnerabilities in coronavirus glycan shields despite extensive glycosylation |
| T2 | 79-87 | Sentence | denotes | Abstract |
| T3 | 88-265 | Sentence | denotes | Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 88-121 | Disease | denotes | Severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T2 | 123-127 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 2 | 19-30 | Species | denotes | coronavirus | Tax:11118 |
| 3 | 31-37 | Chemical | denotes | glycan | MESH:D011134 |
| 39 | 88-121 | Disease | denotes | Severe acute respiratory syndrome | MESH:D045169 |
| 40 | 123-127 | Disease | denotes | SARS | MESH:D045169 |
| 25 | 133-186 | Species | denotes | Middle East respiratory syndrome (MERS) coronaviruses | Tax:1335626 |
| 68 | 173-186 | Species | denotes | coronaviruses | Tax:11118 |
| 69 | 188-192 | Species | denotes | CoVs | Tax:11118 |
| 26 | 188-192 | Species | denotes | CoVs | Tax:11118 |
| 41 | 198-206 | Disease | denotes | zoonotic | MESH:D015047 |
LitCovid-sample-PD-GO-BP-0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 64-77 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
LitCovid-sample-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 64-77 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 64-77 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-77 | Sentence | denotes | Vulnerabilities in coronavirus glycan shields despite extensive glycosylation |
| T2 | 79-87 | Sentence | denotes | Abstract |
| T3 | 88-265 | Sentence | denotes | Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. |